CepTor to Present at BIO InvestorForum 2005.HUNT VALLEY, Md. -- CepTor Corporation, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CEPO CEPO County Emergency Planning Officer (UK) CEPO Community & Environment Project Office (Edmonton Green, North London) ), a development-stage biopharmaceutical company focusing on cell targeted therapeutic products for neuromuscular and neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. , announced today that William Pursley, its Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. will be giving a presentation to investors, analysts, and bankers at the upcoming Bio InvestorForum on October 20, 2005 at 12:40 P.M. Pacific Time in the Presidio room. Top life science growth companies will be in attendance at the Bio InvestorForum, which is being held at the Palace Hotel, San Francisco The current ("New") Palace Hotel (opened in 1909) is an historic hotel located in San Francisco, California, at the SW corner of Market Street and New Montgomery Street, immediately adjacent to BART's Montgomery Street Station. , Ca. Over 190 public and venture-stage companies will be incorporated in the Forum. About CepTor CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) The most severe form of muscular dystrophy, DMD usually affects young boys and causes progressive muscle weakness, usually beginning in the legs. . The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy. This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion